A Single-centre Study Evaluating the Safety of ViscoGel® and Its Safety and Efficacy as an Adjuvant in Act-HIB® Vaccine Administered by Intramuscular Injection to Healthy Volunteers in a Single-blind Randomised, Parallel-group Design
The purpose of this study is to show that ViscoGel® is safe when administrated alone and as an adjuvant together with Act-HIB® vaccine in healthy volunteers and to evaluate the quantitative and qualitative effect on the immune response.
100 项与 Viscogel AB 相关的临床结果
0 项与 Viscogel AB 相关的专利（医药）
100 项与 Viscogel AB 相关的药物交易
100 项与 Viscogel AB 相关的转化医学
